Bicycle Signs US$1.7 B Immuno-oncology Collaboration with Genentech

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 3 (Table of Contents)

Published: 5 Mar-2020

DOI: 10.3833/pdr.v2020.i3.2518     ISSN: 1756-7874

Section: Research & Development



In a bid to extend its leadership in oncology, Genentech has partnered with Bicycle Therapeutics to discover, develop and commercialise immuno-oncology therapies based on the latter’s bicyclic peptide (Bicycle®) technology...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details